Immunotherapy News and Research

Latest Immunotherapy News and Research

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

AMGEN announces additional results from talimogene laherparepvec Phase 3 trial

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

First Phase II study: Everolimus drug slows spread of advanced papillary kidney cancer

Inflammatory marker may highlight aggressive RCC treatment need

Inflammatory marker may highlight aggressive RCC treatment need

Tips for reducing allergens in yards

Tips for reducing allergens in yards

LSDF announces Proof of Concept grants to speed up promising health-related technologies

LSDF announces Proof of Concept grants to speed up promising health-related technologies

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

New method to target, eliminate cancer-supporting macrophages in mouse tumors

New method to target, eliminate cancer-supporting macrophages in mouse tumors

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Myeloid derived suppressor cells provide niche where cancer stem cells survive

Myeloid derived suppressor cells provide niche where cancer stem cells survive

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.